Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Devimistat with Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
NCT03435289Phase 1Unknown
- Sponsor
- Atlantic Health System
- Start
- Oct 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of devimistat in pancreatic cancer (PC), sponsored by Atlantic Health System. Primary endpoint: Maximum Tolerated Dose at 1 year. Status: unknown.
02
Drugs
devimistat
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03435289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03435289.